Autoreactive CD4+ T lymphocyte specific for Type 1 Diabetes-associated autoantigens (T1D-specific CD4+ T cell)

Autoreactive CD4+ T cells specific for Type 1 Diabetes (T1D)-associated autoantigens are a specialized population of T lymphocytes that play a central role in the autoimmune destruction of pancreatic beta cells. These cells recognize peptides derived from islet-specific proteins, such as proinsulin, glutamic acid decarboxylase 65 (GAD65), and zinc transporter 8 (ZnT8), which are presented by high-risk HLA class II molecules like HLA-DR4 and HLA-DQ8 (Source 1.1.1, 1.5.1). Upon activation, these T cells differentiate into proinflammatory subsets (e.g., Th1 and Th17) and secrete cytokines like IFN-gamma and TNF-alpha, which recruit and activate other immune effectors, including CD8+ cytotoxic T cells and macrophages (Source 1.1.2, 1.5.2). This process leads to chronic inflammation of the islets, known as insulitis, and the progressive loss of insulin-producing capacity. Therapeutic targeting of these cells is a major focus in T1D research, aiming to preserve residual beta-cell function and delay disease progression. Drugs such as Teplizumab, an anti-CD3 monoclonal antibody, work by depleting or modulating these effector T cells and promoting the expansion of regulatory T cells (Tregs) (Source 1.4.2, 1.4.3). Other approaches include costimulation blockade with Abatacept and experimental antigen-specific immunotherapies designed to induce immune tolerance to specific islet antigens (Source 1.2.1, 1.5.3). Monitoring these cells using MHC class II tetramers and TCR sequencing serves as a critical biomarker for assessing disease risk and therapeutic efficacy (Source 1.2.2, 1.2.4).

Other names

Diabetogenic CD4+ T cellsIslet-reactive CD4+ T cellsIAR CD4+ T cellsProinsulin-specific CD4+ T cellsGAD65-specific CD4+ T cellsIA-2 specific CD4+ T cellsZnT8-specific CD4+ T cellsHybrid insulin peptide-reactive CD4+ T cells

Therapeutic strategies include the depletion of effector T cells, induction of anergy or exhaustion, expansion of regulatory T cells (Tregs), and blockade of costimulatory signals required for T cell activation.